LTZ Therapeutics
Next-gen myeloid engager immunotherapies
About
Founded in 2023, LTZ Therapeutics is a biotech company advancing novel myeloid engager-based immunotherapies to treat cancer and autoimmune diseases. The company focuses on developing its innate immune engager platform to create innovative drug candidates, progressing from discovery through preclinical to early clinical trials. LTZ's business model centers on proprietary drug development supported by multiple financing rounds to support clinical advancement and global team expansion, aiming to address critical unmet medical needs in oncology and immunology.
Products
-
Myeloid Engager Platform
— Engages myeloid cells to activate tumor cell killing and reprogram the tumor microenvironment for enhanced anti-tumor immunity.
Customer sectors: biotech researchers, pharmaceutical developers, oncology clinicians
-
LTZ-232
— Investigational drug targeting advanced metastatic colorectal cancer and other solid tumors to improve patient outcomes.
Customer sectors: oncology clinicians, clinical researchers, pharmaceutical developers
Market research & competitive positioning
Source-backed TAM / SAM / SOM sizing, displacement analysis, and an interactive peer positioning map for LTZ Therapeutics — available to members.
Related Companies
Other startups in Biotech & Therapeutics
